Oceania · Markets & Finance · Stockhead

Alterity’s biomarker-adjusted Phase 2 analysis shows ~52pc slowing of MSA decline

Published by Stockhead · Australia 5 h ago

The analysis also showed that a biomarker of disease severity predicted how quickly patients declined. ... Read More The post Alterity’s biomarker-adjusted Phase 2 analysis shows…

Read the full article on Stockhead Sign in to save

MediaNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (stockhead.com.au)

Also worth reading

Business News (WA)

Wide Open Agriculture releases study for $311m WA lupin processor

Fat Tail Daily

Firmus IPO: Who’s the exit liquidity?

SmartCompany

‘State-controlled food distribution’: Indie grocers blast $25 billion plan for government-owned supermarkets

The Motley Fool Australia

6 costly mistakes that will slash your Age Pension payment

Startup Daily

Anthropic takes a sly dig at OpenAI before parliamentary inquiry

Financial Standard